Dr Reddy's Laboratories Ltd has completed the acquisition of Habitrol brand (an over-the-counter nicotine replacement therapy transdermal patch) from Novartis Consumer Health Inc.
The Hyderabad-based company had earlier entered into an asset purchase agreement with Novartis Consumer Health Inc to acquire the title and rights of Habitrol® brand and to market the product in the US market.
With this closure, the company has assumed responsibility for the product and will commence shipments of the product in the market shortly, according to a release issued here on Friday.
COMMENT NOW
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.